Amplia Therapeutics Limited (ATX.XA)
| Previous close | 0.1500 |
| Open | 0.1450 |
| Bid | 0.1450 x N/A |
| Ask | 0.1500 x N/A |
| Day's range | 0.1400 - 0.1450 |
| 52-week range | 0.0550 - 0.1800 |
| Volume | |
| Avg. volume | 491,195 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0250 |
| Earnings date | 18 Nov 2024 - 22 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireFDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER
Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia's Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.
Simply Wall St.Allan Moss Buys 40% More Amplia Therapeutics Shares
Investors who take an interest in Amplia Therapeutics Limited ( ASX:ATX ) should definitely note that insider Allan...
PR NewswireFDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.
